Study: NCT05141149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1510 (400mg/16mL)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m^2)
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.